Supports pharmacodynamic, pharmacokinetic, and efficacy studies of small molecule or biologic therapeutic agents. Research should demonstrate sufficient biological activity to justify further development for neurological disorders, aging-related diseases, or non-opioid analgesics with minimal addiction liability. Efficacy testing may use validated in vivo models or New Approach Methodologies. Applications are not currently solicited, allowing time for collaboration development.
Eligible applicants include a wide range of U.S. government entities, educational institutions, nonprofits, for-profit organizations, tribal governments, and certain non-U.S. entities. Specific eligibility details are provided in the full announcement.
